Alder Biopharmaceuticals’ (ALDR) “Neutral” Rating Reiterated at Credit Suisse Group

Share on StockTwits

Credit Suisse Group restated their neutral rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a research note released on Wednesday morning, Briefing.com Automated Import reports.

Other analysts also recently issued research reports about the company. BidaskClub downgraded Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 9th. Mizuho set a $100.00 target price on PRA Health Sciences and gave the company a hold rating in a research note on Friday, May 3rd. Zacks Investment Research raised HB Fuller from a sell rating to a hold rating in a research note on Wednesday, July 3rd. Svb Leerink began coverage on Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They set an outperform rating on the stock. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $25.00 target price on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company. Alder Biopharmaceuticals has a consensus rating of Buy and an average target price of $19.82.

Shares of Alder Biopharmaceuticals stock opened at $11.45 on Wednesday. The firm’s fifty day simple moving average is $11.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 8.34 and a current ratio of 8.34. Alder Biopharmaceuticals has a 1-year low of $9.44 and a 1-year high of $20.87.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.47). On average, research analysts forecast that Alder Biopharmaceuticals will post -4.43 EPS for the current fiscal year.

In other news, EVP James B. Bucher sold 1,897 shares of Alder Biopharmaceuticals stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the transaction, the executive vice president now directly owns 11,706 shares in the company, valued at approximately $162,128.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 15.40% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. Rhumbline Advisers lifted its position in Alder Biopharmaceuticals by 77.3% during the fourth quarter. Rhumbline Advisers now owns 97,762 shares of the biopharmaceutical company’s stock worth $1,002,000 after buying an additional 42,624 shares during the period. LPL Financial LLC raised its holdings in shares of Alder Biopharmaceuticals by 43.4% in the 4th quarter. LPL Financial LLC now owns 18,175 shares of the biopharmaceutical company’s stock worth $186,000 after purchasing an additional 5,500 shares during the period. Hsbc Holdings PLC purchased a new position in shares of Alder Biopharmaceuticals in the 4th quarter worth about $176,000. Dimensional Fund Advisors LP raised its holdings in shares of Alder Biopharmaceuticals by 22.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,162,005 shares of the biopharmaceutical company’s stock worth $11,910,000 after purchasing an additional 215,098 shares during the period. Finally, Stifel Financial Corp purchased a new position in shares of Alder Biopharmaceuticals in the 4th quarter worth about $154,000.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.

Featured Article: How to calculate compound interest

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply